Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 4

BIOSPECIFICS TECHNOLOGIES CORP Form 4 December 01, 2009 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Check this box if no longer subject to

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

(Print or Type Responses)

Section 16.

Form 4 or

Form 5

1(b).

]			2. Issuer Name and Ticker or Trading Symbol BIOSPECIFICS TECHNOLOGIES CORP [BSTC]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) C/O TOBY BOCAIRE	WEGMAN, 409	(Middle) 92	3. Date of Earliest Transaction (Month/Day/Year) 11/27/2009					Director X 10% Owner Officer (give title Other (specify below)				
				4. If Amendment, Date Original Filed(Month/Day/Year)					 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)	(State)	(Zip)	⁽⁾⁾ Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deeme Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8) Code V	4. Securitio on(A) or Disp (Instr. 3, 4)	posed o	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock, \$0.001 par value	11/27/2009			S <u>(1)</u>	100,000	D		1,155,179	Ι	Held by the S.J.Wegman Company (1)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amou Unde Secur	le and int of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address		Relationsh						
1	Director	10% Owner	Officer	Other				
Estate of Edwin H. Wegman C/O TOBY WEGMAN 4092 BOCAIRE BLVD. BOCA RATON, FL 33487		Х						
Signatures								
/s/ Toby Wegman	12/01/2009							
<u>**</u> Signat	Date							
/s/ Thomas L. Wegman as Co- Wegman	12/01/2009							
<u>**</u> Signat	Date							

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On November 27, 2009, the estate of Edwin H. Wegman sold 100,000 shares of the Issuer's common stock held by the S.J. Wegman Company, a New York limited partnership, in a private transaction.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.